Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors

Nanomedicine

Volumn 9, Issue 14, 2014, Pages 2099-2108

  Noble, Charles O ^a,b   Krauze, Michal T ^c   Drummond, Daryl C ^b   Forsayeth, John ^c   Hayes, Mark E ^b   Beyer, Janine ^c   Hadaczek, Piotr ^c   Berger, Mitchel S ^c   Kirpotin, Dmitri B ^b   Bankiewicz, Krystof S ^c   Park, John W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERRIMACK PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug delivery; Glioma; Irinotecan; Liposome; Nanoliposome; Nanoparticle

Indexed keywords

ANION EXCHANGE RESIN; CATION EXCHANGE RESIN; DISTEAROYLPHOSPHATIDYLCHOLINE; IRINOTECAN; POLACRILIN; SEPHADEX; TRIETHYLAMINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; LIPOSOME; NANOMATERIAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CELL SUSPENSION; CONTROLLED STUDY; EVAPORATION; GEL PERMEATION CHROMATOGRAPHY; HISTOPATHOLOGY; INTRACRANIAL TUMOR; ION EXCHANGE CHROMATOGRAPHY; MOUSE; NONHUMAN; PARENCHYMA; PARTICLE SIZE; PHARMACOKINETICS; SURVIVAL TIME; TUMOR CELL INOCULATION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; METABOLISM; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; LIPOSOMES; NANOSTRUCTURES; RATS;

EID: 84911479481     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/NNM.13.201     Document Type: Article

References (60)

1. Fisher PG, Buffler PA. Malignant gliomas in 2005: where to GO from here? JAMA 293(5), 615-617 (2005).
2. Reardon DA, Friedman HS, Powell JBJ, Gilbert M, Yung WK. Irinotecan: promising activity in the treatment of malignant glioma. Oncology 17(5 Suppl. 5), 9-14 (2003).
3. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J. Neurooncol. 40(2), 151-160 (1998).
4. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34(1), 207-217 (1967).
5. Pardridge WM. Molecular biology of the blood-brain barrier. Mol. Biotech. 30(1), 57-69 (2005).
6. Drummond DC, Meyer O, Hong KL, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51(4), 691-743 (1999).
7. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
8. Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM. The role of PEGylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 18(9), 1022-1031 (2013).
9. Gabizon A, Isacson R, Libson E et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 33, 779-786 (1994).
10. Thigpen JT, Aghajanian CA, Alberts DS et al. Role of PEGylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol. 96(1), 10-18 (2005).
11. Rose PG. PEGylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10(3), 205-214 (2005).
12. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. PEGylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 106(4), 848-858 (2006).
13. Al-Batran SE, Bischoff J, von Minckwitz G et al. The clinical benefit of PEGylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre Phase II trial. Br. J. Cancer 94(11), 1615-1620 (2006).
14. Rodriguez MA, Pytlik R, Kozak T et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal Phase 2 study. Cancer 115(15), 3475-3482 (2009).
15. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 72(4), 896-904 (1995).
16. Webb MS, Logan P, Kanter PM et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother. Pharmacol. 42(6), 461-470 (1998).
17. Drummond DC, Marx C, Guo Z et al. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2- targeted immunoliposomes. Clin. Cancer Res. 11(9), 3392-3401 (2005).
18. Drummond DC, Noble CO, Guo Z et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 66(6), 3271-3277 (2006).
19. Drummond DC, Noble CO, Guo Z et al. Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J. Pharmacol. Exp. Ther. 328(1), 321-330 (2009).
20. Noble CO, Guo Z, Hayes ME et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother. Pharmacol. 64(4), 741-751 (2009).
21. Noble CO, Krauze MT, Drummond DC et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 66(5), 2801-2806 (2006).
22. Ko AH, Tempero MA, Shan YS et al. A multinational Phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br. J. Cancer 109(4), 920-925 (2013).
23. Roy AC, Park SR, Cunningham D et al. A randomized Phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann. Oncol. 24(6), 1567-1573 (2013).
24. Prados MD, Yung WK, Jaeckle KA et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 6(1), 44-54 (2004).
25. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50(6), 1715-1720 (1990).
26. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8(3), 641-661 (2002).
27. Mathijssen RHJ, van Alphen RJ, Verweij J et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7(8), 2182-2194 (2001).
28. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res. 54(24), 6330-6333 (1994).
29. Cecchin E, Corona G, Masier S et al. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin. Cancer Res. 11(19 Pt 1), 6901-6907 (2005).
30. Krauze MT, Noble CO, Kawaguchi T et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 9(4), 393-403 (2007).
31. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 3(2), 90-105, 151 (2003).
32. Huynh GH, Deen DF, Szoka FC Jr. Barriers to carrier mediated drug and gene delivery to brain tumors. J. Control. Release 110(2), 236-259 (2006).
33. Huang SK, Martin FJ, Jay G et al. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV Tat gene. Am. J.?Path. 143, 10-14 (1993).
34. Stapleton S, Allen C, Pintilie M, Jaffray DA. Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes. J. Control. Release 172(1), 351-357 (2013).
35. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb. Exp. Pharmacol. (197), 3-53 (2010).
36. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95(8), 4607-4612 (1998).
37. Pluen A, Boucher Y, Ramanujan S et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl Acad. Sci. USA 98(8), 4628-4633 (2001).
38. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain-tumor model - biodistribution and therapeutic efficacy. J. Neurosurg. 83(6), 1029-1037 (1995).
39. Arnold RD, Mager DE, Slack JE, Straubinger RM. Effect of repetitive administration of doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin. Cancer Res. 11(24 Pt 1), 8856-8865 (2005).
40. Verreault M, Strutt D, Masin D et al. Irinophore C, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. J. Control. Release 158(1), 34-43 (2012).
41. Verreault M, Strutt D, Masin D et al. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C), doxorubicin (Caelyx(R)) or vincristine. BMC Cancer 11(124), 124 (2011).
42. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J. Chromatogr. B Biomed. Sci. Appl. 691(1), 161-171 (1997).
43. Bartlett GR. Phosphorus assay in column chromatography. J. Biol. Chem. 234(3), 466-468 (1959).
44. Messerer CL, Ramsay EC, Waterhouse D et al. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin. Cancer Res. 10(19), 6638-6649 (2004).
45. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Biopharmacol. 52(7), 1103-1111 (1996).
46. Humerickhouse R, Lohrbach K, Li L, Bornson WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60(5), 1189-1192 (2000).
47. Hennebelle I, Terret C, Chatelut E et al. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitrophenylacetate converting carboxylesterase activity. Anticancer Drugs 11(6), 465-470 (2000).
48. Atsumi R, Okazaki O, Hakusui H. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model. Biol. Pharm. Bull. 18(7), 1024-1026 (1995).
49. Guichart S, Terret C, Hennebelle I et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. Br. J. Cancer 80(3/4), 364-370 (1999).
50. Chen TC, Su S, Fry D, Liebes L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 97(9), 2363-2373 (2003).
51. Wang W, Ghandi A, Liebes L et al. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation. J. Neurosurg. 114(3), 689-694 (2007).
52. Needham LA, Davidson AH, Bawden LJ et al. Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. J. Pharmacol. Exp. Ther. 339(1), 132-142 (2011).
53. Saito R, Krauze MT, Bringas J et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp. Neurol. 196(2), 381-389 (2005).
54. MacKay JA, Deen DF, Szoka FC. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. 1035(2), 139-153 (2005).
55. Bobo RH, Laske DW, Akbasak A et al. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA 91(6), 2076-2080 (1994).
56. Chen PY, Ozawa T, Drummond DC et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 15(2), 189-197 (2013).
57. Gupta B, Torchilin VP. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother. 56(8), 1215-1223 (2007).
58. Mamot C, Drummond DC, Noble CO et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 65(24), 11631-11638 (2005).
59. Nellis DF, Ekstrom DL, Kirpotin DB et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol. Prog. 21(1), 205-220 (2005).
60. Nellis DF, Giardina SL, Janini GM et al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-Lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol. Prog. 21(1), 221-232 (2005).